178 related articles for article (PubMed ID: 10744046)
21. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.
Yu R; Xiang X; Tan Z; Zhou Y; Wang H; Deng G
Sci Rep; 2016 Oct; 6():35050. PubMed ID: 27731353
[TBL] [Abstract][Full Text] [Related]
23. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
Murata K; Sakamoto A
Int J Oncol; 2008 Dec; 33(6):1149-55. PubMed ID: 19020747
[TBL] [Abstract][Full Text] [Related]
24. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
[TBL] [Abstract][Full Text] [Related]
25. A resected case of metachronous liver metastasis from lung cancer producing alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist II (PIVKA-II).
Oshiro Y; Takada Y; Enomoto T; Fukao K; Ishikawa S; Iijima T
Hepatogastroenterology; 2004; 51(58):1144-7. PubMed ID: 15239263
[TBL] [Abstract][Full Text] [Related]
26. Laboratory assessment of vitamin K status.
Card DJ; Gorska R; Harrington DJ
J Clin Pathol; 2020 Feb; 73(2):70-75. PubMed ID: 31862867
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma.
Ajisaka H; Shimizu K; Miwa K
J Surg Oncol; 2003 Oct; 84(2):89-93. PubMed ID: 14502782
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
29. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
[TBL] [Abstract][Full Text] [Related]
31. The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.
Kang KH; Kim JH; Kang SH; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Gut Liver; 2015 Mar; 9(2):224-30. PubMed ID: 25473073
[TBL] [Abstract][Full Text] [Related]
32. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
33. Tissue distribution of K-vitamers under different nutritional regimens in the rat.
Ronden JE; Thijssen HH; Vermeer C
Biochim Biophys Acta; 1998 Jan; 1379(1):16-22. PubMed ID: 9468327
[TBL] [Abstract][Full Text] [Related]
34. Comparative metabolism of phylloquinone and menaquinone-9 in rat liver.
Will BH; Suttie JW
J Nutr; 1992 Apr; 122(4):953-8. PubMed ID: 1552370
[TBL] [Abstract][Full Text] [Related]
35. Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis.
Ono M; Ohta H; Ohhira M; Sekiya C; Namiki M
Tumour Biol; 1990; 11(6):319-26. PubMed ID: 2173855
[TBL] [Abstract][Full Text] [Related]
36. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
38. Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.
Sohn A; Kim H; Yeo I; Kim Y; Son M; Yu SJ; Yoon JH; Kim Y
J Pharm Biomed Anal; 2018 Jul; 156():142-146. PubMed ID: 29702392
[TBL] [Abstract][Full Text] [Related]
39. Plasma concentrations of vitamin K1 and PIVKA-II in bottle-fed and breast-fed infants with and without vitamin K prophylaxis at birth.
Widdershoven J; Lambert W; Motohara K; Monnens L; de Leenheer A; Matsuda I; Endo F
Eur J Pediatr; 1988 Nov; 148(2):139-42. PubMed ID: 3234435
[TBL] [Abstract][Full Text] [Related]
40. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
Qin X; Tang G; Gao R; Guo Z; Liu Z; Yu S; Chen M; Tao Z; Li S; Liu M; Wang L; Hou L; Xia L; Cheng X; Han J; Qiu L
Int J Lab Hematol; 2017 Aug; 39(4):392-401. PubMed ID: 28318145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
